| ADI | Acceptable daily intake |
| BMI | Body mass index |
| CPIR | Cephalic phase insulin response |
| EFSA | European Food Safety Authority |
| FDA | Food and Drug Administration |
| GLP-1 | Glucagon-like peptide 1 |
| GRAS | Generally recognized as safe |
| HbA1c | Hemoglobin A1C |
| HDL-c | High-density lipoprotein cholesterol |
| IR | Insulin resistance |
| JECFA | Joint FAO/WHO Expert Committee on Food Additives |
| LDL-c | Low-density lipoprotein cholesterol |
| OGTT | Oral glucose tolerance test |
| ND | No statistical differences detected |
| NGO | Non-governmental organization |
| NNS(s) | Non-nutritive sweetener(s) |
| PYY | Peptide YY |
| RCT(s) | Randomized controlled trial(s) |
| Reb | Rebaudioside |
| SCFAs | Short-chain fatty acids |
| TC | Total cholesterol |
| TG | Triglyceride |
| VLDL-c | Very-low-density lipoprotein-cholesterol |
| WHO-NUGAG | World Health Organization Nutrition Guidance Expert Advisory Committee |